These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 36158587)

  • 1. Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan.
    Yau T; Tai D; Chan SL; Huang YH; Choo SP; Hsu C; Cheung TT; Lin SM; Yong WP; Lee J; Leung T; Shum T; Yeung CSY; Tai AY; Law ALY; Cheng AL; Chen LT
    Liver Cancer; 2022 Sep; 11(5):426-439. PubMed ID: 36158587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021.
    Cheung TT; Yu SC; Chan SL; Poon RTP; Kwok P; Lee AS; Tai A; Tam D; Cheung CC; Lai TW; Chia NH; Law A; Shum T; Lam YK; Lau V; Lee V; Chong C; Tang CN; Yau T
    Hepatobiliary Surg Nutr; 2023 Jun; 12(3):366-385. PubMed ID: 37351136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma.
    Cheung TT; Kwok PC; Chan S; Cheung CC; Lee AS; Lee V; Cheng HC; Chia NH; Chong CCN; Lai TW; Law ALY; Luk MY; Tong CC; Yau TCC
    Liver Cancer; 2018 Mar; 7(1):40-54. PubMed ID: 29662832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in systemic therapy for the first-line treatment of unresectable HCC.
    Vogel A; Bathon M; Saborowski A
    Expert Rev Anticancer Ther; 2021 Jun; 21(6):621-628. PubMed ID: 33499684
    [No Abstract]   [Full Text] [Related]  

  • 5. Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements.
    Sun Y; Zhang W; Bi X; Yang Z; Tang Y; Jiang L; Bi F; Chen M; Cheng S; Chi Y; Han Y; Huang J; Huang Z; Ji Y; Jia L; Jiang Z; Jin J; Jin Z; Li X; Li Z; Liang J; Liu L; Liu Y; Lu Y; Lu S; Meng Q; Niu Z; Pan H; Qin S; Qu W; Shao G; Shen F; Song T; Song Y; Tao K; Tian A; Wang J; Wang W; Wang Z; Wu L; Xia F; Xing B; Xu J; Xue H; Yan D; Yang L; Ying J; Yun J; Zeng Z; Zhang X; Zhang Y; Zhang Y; Zhao J; Zhou J; Zhu X; Zou Y; Dong J; Fan J; Lau WY; Sun Y; Yu J; Zhao H; Zhou A; Cai J
    Liver Cancer; 2022 Jun; 11(3):192-208. PubMed ID: 35949289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for the management of advanced and metastatic renal cell carcinoma: joint consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.
    Poon DMC; Chan CK; Chan K; Chu WH; Kwong PWK; Lam W; Law KS; Lee EKC; Liu PL; Sze HCK; Wong JHM; Chan ESY
    Hong Kong Med J; 2022 Dec; 28(6):475-481. PubMed ID: 35815480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hong Kong consensus recommendations on the management of hepatocellular carcinoma.
    Poon RT; Cheung TT; Kwok PC; Lee AS; Li TW; Loke KL; Chan SL; Cheung MT; Lai TW; Cheung CC; Cheung FY; Loo CK; But YK; Hsu SJ; Yu SC; Yau T
    Liver Cancer; 2015 Mar; 4(1):51-69. PubMed ID: 26020029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert Opinion.
    Ogasawara S; Choo SP; Li JT; Yoo C; Wang B; Lee D; Chow PKH
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in pharmacotherapeutics for hepatocellular carcinoma.
    Cerrito L; Santopaolo F; Monti F; Pompili M; Gasbarrini A; Ponziani FR
    Expert Opin Pharmacother; 2021 Jul; 22(10):1343-1354. PubMed ID: 33637024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.
    Kudo M; Kawamura Y; Hasegawa K; Tateishi R; Kariyama K; Shiina S; Toyoda H; Imai Y; Hiraoka A; Ikeda M; Izumi N; Moriguchi M; Ogasawara S; Minami Y; Ueshima K; Murakami T; Miyayama S; Nakashima O; Yano H; Sakamoto M; Hatano E; Shimada M; Kokudo N; Mochida S; Takehara T
    Liver Cancer; 2021 Jun; 10(3):181-223. PubMed ID: 34239808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field.
    Doycheva I; Thuluvath PJ
    J Clin Exp Hepatol; 2019; 9(5):588-596. PubMed ID: 31695249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging drugs for the treatment of hepatocellular carcinoma.
    Ayoub WS; Jones PD; Yang JD; Martin P
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):141-149. PubMed ID: 35642526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Asia Pacific Consensus Statement on Laparoscopic Liver Resection for Hepatocellular Carcinoma: A Report from the 7th Asia-Pacific Primary Liver Cancer Expert Meeting Held in Hong Kong.
    Cheung TT; Han HS; She WH; Chen KH; Chow PKH; Yoong BK; Lee KF; Kubo S; Tang CN; Wakabayashi G
    Liver Cancer; 2018 Mar; 7(1):28-39. PubMed ID: 29662831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.
    Ahmed F; Onwumeh-Okwundu J; Yukselen Z; Endaya Coronel MK; Zaidi M; Guntipalli P; Garimella V; Gudapati S; Mezidor MD; Andrews K; Mouchli M; Shahini E
    World J Gastrointest Oncol; 2021 Nov; 13(11):1813-1832. PubMed ID: 34853653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).
    Sun HC; Zhou J; Wang Z; Liu X; Xie Q; Jia W; Zhao M; Bi X; Li G; Bai X; Ji Y; Xu L; Zhu XD; Bai D; Chen Y; Chen Y; Dai C; Guo R; Guo W; Hao C; Huang T; Huang Z; Li D; Li G; Li T; Li X; Li G; Liang X; Liu J; Liu F; Lu S; Lu Z; Lv W; Mao Y; Shao G; Shi Y; Song T; Tan G; Tang Y; Tao K; Wan C; Wang G; Wang L; Wang S; Wen T; Xing B; Xiang B; Yan S; Yang D; Yin G; Yin T; Yin Z; Yu Z; Zhang B; Zhang J; Zhang S; Zhang T; Zhang Y; Zhang Y; Zhang A; Zhao H; Zhou L; Zhang W; Zhu Z; Qin S; Shen F; Cai X; Teng G; Cai J; Chen M; Li Q; Liu L; Wang W; Liang T; Dong J; Chen X; Wang X; Zheng S; Fan J;
    Hepatobiliary Surg Nutr; 2022 Apr; 11(2):227-252. PubMed ID: 35464283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
    Wang EA; Stein JP; Bellavia RJ; Broadwell SR
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
    Bangaru S; Marrero JA; Singal AG
    Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Therapy in Metastatic Hepatocellular Carcinoma.
    Elms D; Badami A; Dhanarajan A
    Curr Gastroenterol Rep; 2022 May; 24(5):65-71. PubMed ID: 35416635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Post-International Gastrointestinal Cancers' Conference (IGICC) Position Statements.
    Yalcin S; Lacin S; Kaseb AO; Peynircioğlu B; Cantasdemir M; Çil BE; Hurmuz P; Doğrul AB; Bozkurt MF; Abali H; Akhan O; Şimşek H; Sahin B; Aykan FN; Yücel İ; Tellioğlu G; Selçukbiricik F; Philip PA
    J Hepatocell Carcinoma; 2024; 11():953-974. PubMed ID: 38832120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014).
    Ho MC; Hasegawa K; Chen XP; Nagano H; Lee YJ; Chau GY; Zhou J; Wang CC; Choi YR; Poon RT; Kokudo N
    Liver Cancer; 2016 Oct; 5(4):245-256. PubMed ID: 27781197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.